Related Experiment Video
Updated: Jun 4, 2026
06:01
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
Published on: January 7, 2019
Detecting and quantifying multiple proteins in clinical samples in high-throughput using antibody microarrays.
Tanya Knickerbocker1, Gavin MacBeath
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA. knickerb@fas.harvard.edu
Methods in Molecular Biology (Clifton, N.J.)
|March 4, 2011
Summary
Analyzing multiple protein markers with antibody microarrays significantly improves disease prediction accuracy. This approach enhances prognostic reliability for conditions like end-stage renal disease, moving beyond single-marker limitations.
Area of Science:
- Biochemistry and Molecular Biology
- Clinical Diagnostics
- Proteomics
Background:
- Current clinical diagnostics often rely on single protein quantification via immunoassays, which have limitations in predictive accuracy, especially for complex or early-stage diseases.
- Single-marker analysis is insufficient for reliable prediction in monogenic diseases and less accurate for polygenic diseases or early detection.
- Simultaneous analysis of multiple markers shows a dramatic increase in predictive reliability.
Purpose of the Study:
- To investigate the utility of antibody microarrays for simultaneous quantification of multiple protein markers.
- To identify prognostic markers for early mortality in patients with end-stage renal disease (ESRD).
- To develop multivariate models for improved disease prediction using identified markers.
Main Methods:
- Utilized antibody microarrays for high-throughput, simultaneous protein quantification in various sample types (serum, urine, tissue).
- Applied the assay to identify prognostic markers associated with early mortality in ESRD patients.
- Constructed multivariate predictive models based on the identified protein markers.
Main Results:
- Successfully identified prognostic markers for early mortality in ESRD patients using antibody microarrays.
- Developed multivariate models demonstrating enhanced predictive reliability compared to single-marker approaches.
- Demonstrated the feasibility of high-throughput, low-sample-volume protein analysis with antibody microarrays.
Conclusions:
- Antibody microarrays offer a powerful, miniaturized, and high-throughput method for multi-protein quantification.
- This technology enables the identification of novel prognostic markers and the development of more accurate predictive models.
- Antibody microarrays show significant potential for clinical diagnostics and discovery-based research, possibly becoming routine in clinical labs.
Related Concept Videos
02:34DNA Microarrays
Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...